buloxibutid

Buloxibutid is a first-in-class, orally available small molecule that acts as a selective agonist of the angiotensin II type 2 receptor (AT2R). Developed by Vicore Pharma, buloxibutid targets the protective arm of the renin-angiotensin system and is being investigated primarily for idiopathic pulmonary fibrosis (IPF). Its mechanism involves stimulating AT2 receptors on alveolar epithelial type 2 cells (AEC2s), which play a central role in lung repair and maintenance. Preclinical studies have shown that buloxibutid improves AEC2 viability, enhances surfactant secretion, supports epithelial repair via replenishment of gas exchange alveolar epithelial type 1 cells (AEC1s), decreases profibrotic signaling, upregulates collagenase matrix metalloproteinases to resolve fibrotic tissue, and addresses vascular dysfunction. Clinical trials have demonstrated improvements in forced vital capacity (FVC) over 36 weeks with good tolerability and no serious adverse events reported[1][2][3][4][5][6][7][8].

Other names

BuloxibutidButyl N-[3-[4-(imidazol-1-ylmethyl)phenyl]-5-(2-methylpropyl)thiophen-2-yl]sulfonylcarbamateButyl 3-(4-((1h-imidazol-1-yl)methyl)phenyl)-5-isobutylthiophen-2 yl sulfonylcarbamate